RecruitingNCT05913141

PDO/PDO-TIL/PDOTS for Drug Screen

Patient-derived Organoids, Patient-derived Organoids-tumor-infiltrating Lymphocyte Coculture System, and Patient-derived Organotypic Tissue Spheroids for Drug Screen

Sponsor

Shanghai Zhongshan Hospital

Enrollment

30 participants

Start Date

Jun 1, 2023

Study Type

OBSERVATIONAL

Conditions

Liver Cancer Metastatic Liver Cancer

Summary

This clinical trial aims to use the patient-derived organoid (PDO), Patient-derived organoids-tumor-infiltrating lymphocyte coculture system (PDO-TIL) and patient-derived organotypic tissue spheroids (PDOTS) to simulate the tumor microenvironment in cancer patients. The culture system can be used for pre-clinical validation of drugs and screening of drugs to treat sensitive people and provide individualized treatment for patients with liver cancer. This model is used to explore the molecular mechanism of drug resistance and to find intervention strategies to further improve the response rate of drugs. This study is expected to provide an ideal platform for drug screening and drug resistance research in liver cancer patients, which can replace experimental animal models, and guide personalized medication for liver cancer patients, so as to improve the overall prognosis of patients.

Eligibility

Min Age: 18 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting tumor samples from liver cancer patients to grow 'mini-tumors' (organoids) in the lab and test which drugs work best — a step toward personalized cancer treatment. **You may be eligible if...** - You are 18 or older - You have liver cancer (primary or metastatic) confirmed clinically or by pathology - You have at least one measurable tumor - You have good performance status (ECOG 0–1) - You are willing to undergo a liver biopsy for the study **You may NOT be eligible if...** - Your liver function is too poor for a biopsy - You have a serious blood clotting disorder - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERDrug screen with PDO/PDO-TIL/PDOTS

Drug screen with patient-derived organoids, patient-derived organoids-tumor-infiltrating lymphocyte coculture system, or patient-derived organotypic tissue spheroids.

Locations(1)

Zhongshan Hospital, Fudan University

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05913141

Related Trials

Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype

NCT067531361 location

Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies

NCT004510221 location